Walder Wyss advised DiNAQOR in its collaboration and license agreement with BioMarin

BioMarin Pharmaceutical announced that the company has entered into a preclinical collaboration and license agreement with DiNAQOR, a gene therapy platform company headquartered in Pfäffikon, to develop novel gene therapies to treat rare genetic cardiomyopathies. DiNAQOR will receive an undisclosed upfront payment and is eligible to receive development, regulatory and commercial milestones on product sales in addition to tiered royalties on worldwide sales.

The team

Walder Wyss advised DiNAQOR on all legal aspects of the transaction, including corporate, IP and life science issues. The team was led by partner Hans Rudolf Trüeb (ip/it) and included senior associate Marion Bähler (corporate/m&a) and associate Florian C. Roth (ip/it).